Maternal and neonatal outcome of labour induction at term comparing two regimens of misoprostol

References

[1] Abramovici D, Goldwasser S, Mabie BC, Mercer BM, Goldwasser R, Sibai BM. A randomized comparison of oral misoprostol versus Foley catheter and oxytocin for induction of labor term. Am J Obstet Gynecol. 1999;181:1108–12.10.1016/S0002-9378(99)70090-6Search in Google Scholar

[2] ACOG Committee Opinion. New US Food and Drug Administration labelling of Cytotec (misoprostol) use in pregnancy. Int J Gynecol Obstet. 2003;82:137–8.Search in Google Scholar

[3] Ande AB, Ezeanochie CM, Olagbuji NB. Induction of labor in prolonged pregnancy with unfavourable cervix: comparison of sequential intracervical Foley catheter-intravaginal misoprostol and intravaginal misoprostol alone. Arch Gynecol Obstet. 2012;285:967–71.10.1007/s00404-011-2094-4Search in Google Scholar

[4] Bennett BB. Uterine rupture during induction of labor at term with intravaginal misoprostol. Obstet Gynecol. 1997;89:832–3.10.1016/S0029-7844(97)00036-7Search in Google Scholar

[5] Caliskan E, Dilbaz S, Gelisen O, Dilbaz B, Ozturk N, Haberal A. Unsuccessful labour induction in women with unfavourable cervical scores: predictors and management. Aust NZ J Obstet Gynaecol. 2004;44:562–7.10.1111/j.1479-828X.2004.00321.xSearch in Google Scholar

[6] Cheng SY, Hsue CS, Hwang GH, Chen W, Li TC. Comparison of labor induction with titrated oral misoprostol solution between nulliparous and multiparous women. J Obstet Gynaecol Res. 2010;36:72–8.10.1111/j.1447-0756.2009.01118.xSearch in Google Scholar

[7] El-Refaey H, Cader I, Wheatley DN, Templeton A. Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost. Lancet. 1994;343:1207–9.10.1016/S0140-6736(94)92406-6Search in Google Scholar

[8] Eroglu D, Oktem M, Yanik F, Kuscu E. Labor induction at term: a comparison of the effects of 50 microg and 25 microg vaginal misoprostol. Clin Exp Obstet Gynecol. 2007;34:102–5.Search in Google Scholar

[9] Farah LA, Sanchez-Ramos L, Rosa C, Del Valle GO, Gaudier FL, Delke I, et al. Randomized trial of two doses of the prostaglandin E1 analog misoprostol for labor induction. Am J Obstet Gynecol. 1997;177:364–71.10.1016/S0002-9378(97)70199-6Search in Google Scholar

[10] Has R, Batukan C, Ermis H, Cevher E, Araman A, Kilic G, et al. Comparison of 25 and 50 μg vaginally administered misoprostol for preinduction of cervical ripening and labor induction. Gynecol Obstet Invest. 2002;53:16–21.10.1159/000049405Search in Google Scholar PubMed

[11] Hofmeyr GJ, Gülmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2010;10:CD000941.10.1002/14651858.CD000941.pub2Search in Google Scholar PubMed PubMed Central

[12] How HY, Laeseburge L, Khoury JC, Siddiqi TA, Spinnato JA, Sibai BM. A comparison of various routes and dosages of misoprostol for cervical ripening and induction of labor. Am J Obstet Gynecol. 2001;185:911–5.10.1067/mob.2001.117358Search in Google Scholar PubMed

[13] Kehl S, Ehard A, Berlit S, Spaich S, Sütterlin M, Siemer J. Combination of misoprostol and mechanical dilation for induction of labour: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2011;159:315–9.10.1016/j.ejogrb.2011.09.010Search in Google Scholar

[14] Kiesewetter B, Lehner R. Maternal outcome monitoring: induction of labour versus spontaneous onset of labour – a retrospective analysis. Arch Gynecol Obstet. 2012;286: 37–41.10.1007/s00404-012-2239-0Search in Google Scholar

[15] Levine LD, Hirshberg A, Srinivas SK. Term induction of labor and risk of cesarean delivery by parity. J Matern Fetal Neonatal Med. 2013. [Epub ahead of print].10.3109/14767058.2013.864274Search in Google Scholar

[16] Loto OM, Ikuomola AA, Ayuba II, Onwudiegwu U. Comparative study of the outcome of induction of labor using 25 μg and 50 μg of vaginal misoprostol. J Matern Fetal Neonatal Med. 2012;25:2359–62.10.3109/14767058.2012.696160Search in Google Scholar

[17] Mazzone ME, Woolever J. Uterine rupture in a patient with an unscarred uterus: a case study. WMJ. 2006;105:64–6.Search in Google Scholar

[18] Meydanli MM, Caliskan E, Burak F, Narin MA, Atmaca R. Labor induction post-term with 25 micrograms vs. 50 micrograms of intravaginal misoprostol. Int J Gynaecol Obstet. 2003;81: 249–55.10.1016/S0020-7292(03)00042-0Search in Google Scholar

[19] Ophir E, Odeh M, Hirsch Y, Bornstein J. Uterine rupture during trial of labor: controversy of induction’s methods. Obstet Gynecol Surv. 2012;67:734–45.10.1097/OGX.0b013e318273feebSearch in Google Scholar

[20] Plaut MM, Schwartz ML, Lubarsky SL. Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Am J Obstet Gynecol. 1999;180:1532–42.10.1016/S0002-9378(99)70049-9Search in Google Scholar

[21] Sanchez-Ramos L, Kaunitz AM, Delke I. Labor induction with 25 μg versus 50 μg intravaginal misoprostol: a systematic review. Obstet Gynecol. 2002;99:145–51.10.1097/00006250-200201000-00026Search in Google Scholar

[22] Senior J, Marshall K, Sangha K, Clayton JK. In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. Br J Pharm. 1993;108:501–6.10.1111/j.1476-5381.1993.tb12832.xSearch in Google Scholar PubMed PubMed Central

[23] Szczesny W, Sandvik L. Pre-induction cervical ripening with 25 μg and 50 μg vaginal misoprostol in 181 nulliparous parturients. J Matern Fetal Neonatal Med. 2009;22:265–8.10.1080/14767050902763142Search in Google Scholar PubMed

[24] Tang OS, Gezell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99:160–7.10.1016/j.ijgo.2007.09.004Search in Google Scholar

[25] Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet. 2013;121:186–9.10.1016/j.ijgo.2012.12.009Search in Google Scholar

[26] Thomas A, Jophy R, Maskhar A, Thomas RK. Uterine rupture in primigravida with misoprostol used for induction of labor. BJOG. 2003;110:217–8.10.1046/j.1471-0528.2003.t01-2-02005.xSearch in Google Scholar

[27] Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med. 1992;327:1575–80.10.1056/NEJM199211263272207Search in Google Scholar

[28] Weeks AD, Fiala C, Safar P. Misoprostol and the debate over off-label drug use. Br J Obstet Gynaecol. 2005;112:269–72.10.1111/j.1471-0528.2004.00490.xSearch in Google Scholar

[29] World Health Organization. WHO model list of essential medicines. 17th ed. Available at: http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf. (Published 2011).Search in Google Scholar

[30] World Health Organization. WHO recommendations for induction of labour. Available at: http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241501156/en/index.html.Search in Google Scholar

[31] Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88–92.10.1016/S0029-7844(97)00111-7Search in Google Scholar

[32] Zimmermann R, Blochinger B, Kurmanavicius J. The electronic maternity notes. Gynaekologe. 2006;39:278–82.10.1007/s00129-006-1812-7Search in Google Scholar